Last updated: February 21, 2026
What is the Drug Associated with NDC 24979-0035?
NDC 24979-0035 is the National Drug Code for Vyvgart (efgartigimod alfa-fcab), a monoclonal antibody developed by Argenx. It is indicated for the treatment of generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor antibody-positive.
Market Size and Dynamics
Current Market Landscape
- Indication: Generalized myasthenia gravis (gMG), a rare autoimmune neuromuscular disorder.
- Prevalence: Approximately 20,000 to 30,000 patients in the U.S.
- Existing Therapies: Include corticosteroids, immunosuppressants, and IVIG/PEX. Efgartigimod provides a targeted approach, potentially reducing side effects associated with broad immunosuppression.
Competitive Environment
| Product |
Mechanism |
Approval Status |
Annual Sales (2022) |
Market Share |
Price Range (per dose) |
| Efgartigimod |
Neonatal Fc receptor (FcRn) inhibitor |
Approved (2021) |
~$300 million* |
Leading among targeted therapies |
~$9,000 – $12,000 |
| Soliris (eculizumab) |
Complement inhibitor |
Approved |
$4 billion (2022) |
Larger overall market |
~$5,000 per dose (intravenous) |
| Mestinon (pyridostigmine) |
Acetylcholinesterase inhibitor |
Approved |
Estimated $250 million |
Symptomatic treatment |
~$50–$100 per month |
*Note: Efgartigimod sales are estimated based on market penetration and recent earnings reports.
Growth Drivers
- Expansion of Approved Indications: Efgartigimod's ongoing trials target additional autoimmune diseases.
- Increased Diagnosis: Growing awareness of gMG and improved diagnostic capabilities expand eligible patient pool.
- Premium Pricing: As the only new targeted therapy, efgartigimod commands higher prices.
- Potential for Biosimilars: Currently, limited biosimilar competition.
Regulatory and Reimbursement Factors
- FDA approval in 2021 positioned efgartigimod as a first-in-class therapy.
- Payer policies favor high-cost biologics with demonstrated clinical benefit.
- Medicaid and private insurers typically reimburse in the $9,000 to $12,000 per dose range.
Price Projections (2023–2028)
Short-term (1–2 years)
- Initial average price per dose: $9,500
- Dosing schedule: Usually weekly, totaling approximately 4 doses per month.
- Monthly expenditure per patient: ~$38,000
- Revenue assuming 10,000 patients: ~$380 million annually.
Mid-term (3–5 years)
- Competition may emerge if biosimilars or alternative therapies enter market.
- Presumed price erosion of 10-15% due to increased competition.
- Predicted average price per dose: $8,000–$8,500.
- Potential expansion into additional autoimmune indications could increase revenues.
Long-term (5+ years)
- Patent exclusivity expiration around 2030.
- Price pressure from biosimilars expected.
- Consolidation of market share may stabilize at a lower price point.
- Estimated annual revenue post-patent expiry: ~$150 million–$200 million, with significant generic/biosimilar competition.
Key Considerations for Stakeholders
- Manufacturers: Maintain patent protection and expand indications.
- Investors: In growth phase, valuation linked to sales growth and pipeline progress.
- Payers: Emphasize demonstrating long-term cost savings over standard therapies to justify high prices.
Summary
NDC 24979-0035 represents Vyvgart, a leading targeted biologic for gMG. Market size is constrained by disease rarity but benefits from high unmet need, enabling premium pricing. Current revenue projections hover around $380 million annually, with prices per dose around $9,500. Price erosion is anticipated as biosimilars emerge, with long-term revenues likely declining unless new indications or combination strategies are developed.
Key Takeaways
- Vyvgart launched in 2021 with high prices (~$9,500/dose).
- Industry sales in 2022 exceeded $300 million.
- Market growth prospects depend on indication expansion, competitive pressures, and biosimilar entry.
- Patent expiration around 2030 could challenge pricing and revenues.
- Stakeholders must monitor regulatory and reimbursement landscapes for strategic planning.
FAQs
1. How does the price of Vyvgart compare to other gMG therapies?
It is significantly higher than symptomatic treatments like pyridostigmine, aligning more with other biologics such as eculizumab, reflecting its targeted mechanism and FDA approval status.
2. What factors could influence the price trajectory significantly?
Introduction of biosimilars, additional FDA approvals, and changes in reimbursement policies.
3. Are there risks related to market adoption?
Yes. Slow adoption, insurance coverage hurdles, or unforeseen adverse effects could hinder growth.
4. How do manufacturing costs impact pricing?
Biologics have high manufacturing costs, but premium pricing covers these expenses, especially for tailored autoimmune therapeutics.
5. What is the potential for Vyvgart in indications beyond gMG?
There are ongoing trials for other autoimmune diseases, which could diversify revenue streams and support sustained pricing.
References
[1] Argenx. (2022). Vyvgart (efgartigimod alfa-fcab) Prescribing Information.
[2] IMS Health. (2022). U.S. Prescription Drug Market Reports.
[3] EvaluatePharma. (2022). Global Oncology and Immunology Market Analysis.
[4] FDA. (2021). Vyvgart (efgartigimod alfa-fcab) Approval Letter.
[5] IQVIA. (2022). Biologic Sales Data.
